Parameter
| Biomarker | CA19-9 | Full name | Carbohydrate antigen 19-9 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, monitoring, prognosis | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum (immunoassay) | ||
| Pathobiological Mechanisms | As a modified Lewis (a) blood group antigen, it is synthesized by exocrine epithelial cells and reflects tumor burden and progression by participating in the formation of tumor-associated glycoproteins and mucin | ||||
| Clinical Availability Status | Clinical available (conventional) : the FDA approved for use in symptomatic patients with diagnosis, treatment effect and recurrence monitoring, European and American guidelines recommend preoperative and postoperative once 3-6 months to 2 years | ||||
| Notes and Dynamics | The most widely used but have limitations, sensitivity 50% 75%, specificity 83%, Lewis antigen negative population (about 10%) in the diagnosis value of joint use with other markers | ||||